CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 37 enrolled
Drug / intervention
Milnacipran +1 moredrug
Likely dose
Milnacipran 12.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01108731
NCT01108731Phase 3Completed
CompareCT.gov

The Effect of Milnacipran or Placebo on Ventricular Lactate Levels and Fibromyalgia Induced "Brain Fog."

Beth Israel Medical Center·interventional·Posted Apr 22, 2010·Updated Jun 30, 2016

In Brief

A Phase 3 clinical trial evaluating Milnacipran and Placebo for Fibromyalgia. Completed, enrolled 37 participants across 1 site.

Detailed Summary

Use of the drug Milnacipran will reduce ventricular lactate levels and processing time for completing complex tasks relative to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 22, 2010
Enrollment StartMar 1, 2010
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 16.2 years ago

Interventions

Milnaciprandrug

Patients will take an increasing number of 12.5mg pills for the first 9 days during the "ramp up" period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study.

Placebodrug

Patients will take an increasing number of placebo pills for the first 9 days during the "ramp up" period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study.